FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
11/09/2024
Back to search
Official data from USPTO
STARPAX BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
STARPAX BIOPHARMA
ST13
US500000079354996Class
5, 42, 44
Filing
79354996
Registration
7333932
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
01/10/2025
Trademark type
Word
Nice classes
5, 42, 44
Filing date
06/20/2022
Registration date
03/26/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/26/2024
Last transaction
01/10/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
CA
Examiner
KAPLAN, VALERIE
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Starpax Biopharma Inc.
Médical Starpax Inc./ Starpax Medical Inc.
Representatives
Michelle P. Ciotola Cantor Colburn LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-cancer preparations; bacteria capable to transport therapeutic agents and imagery markers into cancer tumors and organs for the treatment of cancer and other diseases requiring targeted delivery; bacteria capable to transport therapeutic agents and imagery markers into organs for the treatment of diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and compositions for the treatment and prevention of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and substances for the treatment of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; therapeutic agents and imagery markers for delivery of cancer treatment
Class 42
Pharmaceutical research and development; medical and scientific researchconducting clinical trials for others for pharmaceutical preparations used for the treatment of cancerimmunologicalinflammatory and infectious diseasespain
Class 44
Health care services for treating cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; medical analysis services for cancer diagnosis and prognosis; medical diagnostic services
Publications
History of USPTO decisions and trademark events.
27 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/18/2024
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/17/2024
XXCR
GENERIC MADRID TRANSACTION CREATED
10/16/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/13/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/27/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/26/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/26/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/09/2024
PUBO
PUBLISHED FOR OPPOSITION
01/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/20/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/20/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/20/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2023
RFNP
REFUSAL PROCESSED BY IB
06/26/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/07/2023
RFRR
REFUSAL PROCESSED BY MPU
06/06/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/14/2023
CNRT
NON-FINAL ACTION WRITTEN
04/13/2023
DOCK
ASSIGNED TO EXAMINER
03/30/2023
MAFR
APPLICATION FILING RECEIPT MAILED
11/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/14/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/10/2022
Continuous trademark protection
Get notified about every new filing that threatens STARPAX BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.